{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:09:45Z","timestamp":1789430985714,"version":"build-2803163510"},"reference-count":87,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T00:00:00Z","timestamp":1588982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The high occurrence of bladder cancer and its tendency to recur in combination with a lifelong surveillance make the treatment of superficial bladder cancer one of the most expensive and time-consuming. Moreover, carcinoma in situ often leads to muscle invasion with an unfavorable prognosis. Currently, invasive methods including cystoscopy and cytology remain a gold standard. The aim of this study was to explore urine-based biomarkers to find the one with the best specificity and sensitivity, which would allow optimizing the treatment plan. In this review, we sum up the current knowledge about Cytokeratin fragments (CYFRA 21.1), Excision Repair Cross-Complementation 1 (ERCC1), Tumour Protein p53 (Tp53), Fibroblast Growth Factor Receptor 3 (FGFR3), Tumor-Associated Trypsin Inhibitor (TATI) and their potential applications in clinical practice.<\/jats:p>","DOI":"10.3390\/ijms21093360","type":"journal-article","created":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T10:01:18Z","timestamp":1589191278000},"page":"3360","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Diagnostic and Prognostic Potential of Biomarkers CYFRA 21.1, ERCC1, p53, FGFR3 and TATI in Bladder Cancers"],"prefix":"10.3390","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8050-1507","authenticated-orcid":false,"given":"Milena","family":"Matuszczak","sequence":"first","affiliation":[{"name":"Department of Urology, Collegium Medicum, University of Zielona G\u00f3ra, 65-046 Zielona G\u00f3ra, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8646-1219","authenticated-orcid":false,"given":"Maciej","family":"Salagierski","sequence":"additional","affiliation":[{"name":"Department of Urology, Collegium Medicum, University of Zielona G\u00f3ra, 65-046 Zielona G\u00f3ra, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,5,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA A Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","article-title":"Bladder cancer incidence and mortality: A global overview and recent trends","volume":"71","author":"Antoni","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2017.22","article-title":"Bladder cancer","volume":"3","author":"Sanli","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2016.02.028","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs\u2014Part B: Prostate and bladder tumours","volume":"70","author":"Humphrey","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1146\/annurev-pathol-012513-104703","article-title":"Origins of bladder cancer","volume":"11","author":"Czerniak","year":"2016","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2013.06.003","article-title":"EAU Guidelines on Non\u2013Muscle-invasive urothelial carcinoma of the bladder: Update 2013","volume":"64","author":"Babjuk","year":"2013","journal-title":"Eur. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrc3817","article-title":"Molecular biology of bladder cancer: New insights into pathogenesis and clinical diversity","volume":"15","author":"Knowles","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Inamura, K. (2018). Bladder cancer: New insights into its molecular pathology. Cancers, 10.","DOI":"10.3390\/cancers10040100"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur. Urol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/bju.13760","article-title":"Guideline of guidelines: Non-muscle-invasive bladder cancer","volume":"119","author":"Woldu","year":"2017","journal-title":"BJU Int."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1007\/s13277-015-3352-z","article-title":"Diagnostic accuracy of cytokeratin-19 fragment (CYFRA 21\u20131) for bladder cancer: a systematic review and meta-analysis","volume":"36","author":"Huang","year":"2015","journal-title":"Tumor Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"14329","DOI":"10.1007\/s13277-016-5223-7","article-title":"Cytokeratin-19 fragment in the diagnosis of bladder carcinoma","volume":"37","author":"Guo","year":"2016","journal-title":"Tumor Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.4238\/2015.April.27.6","article-title":"CYFRA21-1 levels could be a biomarker for bladder cancer: A meta-analysis","volume":"14","author":"Kuang","year":"2015","journal-title":"Genet. Mol. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1002\/cncr.10565","article-title":"Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma","volume":"94","author":"Nisman","year":"2002","journal-title":"Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3233\/BLC-160054","article-title":"A systematic review of the diagnostic and prognostic value of urinary protein biomarkers in urothelial bladder cancer","volume":"2","author":"Goldsmith","year":"2016","journal-title":"Bladder Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1097\/01.ju.0000176742.53556.25","article-title":"Serum CYFRA 21\u20131 in patients with invasive bladder cancer and its relevance as a tumor marker during chemotherapy","volume":"174","author":"Andreadis","year":"2005","journal-title":"J. Urol."},{"key":"ref_18","first-page":"4281","article-title":"The follow-up of patients with non-muscle-invasive bladder cancer by urine cytology, abdominal ultrasound and urine CYFRA 21-1: A pilot study","volume":"29","author":"Nisman","year":"2009","journal-title":"Anticancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1159\/000327517","article-title":"Clinical usefulness of CEA, CA19-9, and CYFRA 21-1 as tumor markers for urothelial bladder carcinoma","volume":"87","author":"Washino","year":"2011","journal-title":"Urol. Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1093\/clinchem\/42.10.1634","article-title":"Standardization of assay for cytokeratin-related tumor marker CYFRA21.1 in urine samples","volume":"42","author":"Dittadi","year":"1996","journal-title":"Clin. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.cca.2012.08.018","article-title":"Diagnostic values of urine CYFRA21-1, NMP22, UBC, and FDP for the detection of bladder cancer","volume":"414","author":"Jeong","year":"2012","journal-title":"Clin. Chim. Acta"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.juro.2015.06.099","article-title":"ERCC1 as a prognostic and predictive biomarker for urothelial carcinoma of the bladder following radical cystectomy","volume":"194","author":"Klatte","year":"2015","journal-title":"J. Urol."},{"key":"ref_23","first-page":"4915","article-title":"TP53 and FGFR3 Gene mutation assessment in urine: Pilot study for bladder cancer diagnosis","volume":"35","author":"Noel","year":"2015","journal-title":"Anticancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.3892\/ol.2017.6621","article-title":"Expression levels of FGFR3 as a prognostic marker for the progression of primary pT1 bladder cancer and its association with mutation status","volume":"14","author":"Kang","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Roperch, J.-P., Grandchamp, B., Desgrandchamps, F., Mongiat-Artus, P., Ravery, V., Ouzaid, I., Roupret, M., Phe, V., Ciofu, C., and Tubach, F. (2016). Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive\/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2748-5"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3233\/CBM-182143","article-title":"Prognostic value of the combined expression of tumor-associated trypsin inhibitor (TATI) and p53 in patients with bladder cancer undergoing radical cystectomy","volume":"26","author":"Liu","year":"2019","journal-title":"Cancer Biomark."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.urology.2008.04.009","article-title":"Evaluation of urine tumor-associated trypsin inhibitor, CYFRA 21-1, and urinary bladder cancer antigen for detection of high-grade bladder Carcinoma","volume":"72","author":"Gkialas","year":"2008","journal-title":"Urology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ctrv.2006.09.006","article-title":"Molecular mechanisms of resistance and toxicity associated with platinating agents","volume":"33","author":"Rabik","year":"2007","journal-title":"Cancer Treat. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1158\/1078-0432.CCR-07-2238","article-title":"Platinum resistance: The role of DNA repair pathways","volume":"14","author":"Martin","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.2217\/fon.10.140","article-title":"ERCC1: Impact in multimodality treatment of upper gastrointestinal cancer","volume":"6","author":"Metzger","year":"2010","journal-title":"Future Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1056\/NEJMoa060570","article-title":"DNA repair by ERCC1 in Non\u2013Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy","volume":"355","author":"Olaussen","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1378\/chest.127.3.978","article-title":"ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer","volume":"127","author":"Simon","year":"2005","journal-title":"Chest"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/(SICI)1097-0215(19970620)74:3<330::AID-IJC17>3.0.CO;2-F","article-title":"Reduced survival in patients with stage-I non-small-cell lung cancer associated with DNA-replication errors","volume":"74","author":"Rosell","year":"1997","journal-title":"Int. J. Cancer"},{"key":"ref_34","first-page":"42","article-title":"Gene expression of excision repair cross-complementation group 1 enzyme as a novel predictive marker in patients receiving platinum-based chemotherapy in advanced bladder cancer","volume":"35","author":"Eldehna","year":"2018","journal-title":"Benha Med. J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13000-019-0885-2","article-title":"Low ERCC1 expression is a good predictive marker in lung adenocarcinoma patients receiving chemotherapy based on platinum in all TNM stages\u2014A single-center study","volume":"14","author":"Mladinov","year":"2019","journal-title":"Diagn. Pathol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00280-014-2562-1","article-title":"Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum\u2013paclitaxel chemotherapy","volume":"74","author":"Li","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2041-9414-3-3","article-title":"Deficient expression of DNA repair enzymes in early progression to sporadic colon cancer","volume":"3","author":"Facista","year":"2012","journal-title":"Genome Integr."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1038\/srep04313","article-title":"Measuring ERCC1 protein expression in cancer specimens: Validation of a novel antibody","volume":"4","author":"Smith","year":"2014","journal-title":"Sci. Rep."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Sun, J.-M., Sung, J.-Y., Park, S.H., Kwon, G.Y., Jeong, B.C., Seo, S.I., Jeon, S.S., Lee, H.M., Jo, J., and Choi, H.Y. (2012). ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy. BMC Cancer, 12.","DOI":"10.1186\/1471-2407-12-187"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1016\/S1569-9056(14)60123-8","article-title":"122 ERCC1-negative tumors benefit from neoadjuvant cisplatin-based chemotherapy whereas patients with ERCC1-positive tumors do not\u2014Results from a cystectomy trial database","volume":"13","author":"Hemdan","year":"2014","journal-title":"Eur. Urol. Suppl."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.critrevonc.2017.10.012","article-title":"ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinum based chemotherapy: A systematic review and meta-analysis","volume":"120","author":"Urun","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3892\/mco.2013.85","article-title":"ERCC1 and XRCC1 expression predicts survival in bladder cancer patients receiving combined trimodality therapy","volume":"1","author":"Sakano","year":"2013","journal-title":"Mol. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"6207","DOI":"10.7150\/jca.37335","article-title":"p53\/PCDH17\/Beclin-1 proteins as prognostic predictors for urinary bladder cancer","volume":"10","author":"Chen","year":"2019","journal-title":"J. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.4161\/cc.24128","article-title":"Dissecting the pathways that destabilize mutant p53: The proteasome or autophagy?","volume":"12","author":"Choundhury","year":"2013","journal-title":"Cell Cycle"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.molcel.2014.04.024","article-title":"Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation","volume":"54","author":"Zhou","year":"2014","journal-title":"Mol. Cell"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/1756287216638981","article-title":"Molecular substratification of bladder cancer: Moving towards individualized patient management","volume":"8","author":"Mitra","year":"2016","journal-title":"Ther. Adv. Urol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/cam4.346","article-title":"Discrimination of p53 immunohistochemistry-positive tumors by its staining pattern in gastric cancer","volume":"4","author":"Ando","year":"2014","journal-title":"Cancer Medicine"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1101\/gad.1772909","article-title":"Inactivation of p53 and Pten promotes invasive bladder cancer","volume":"23","author":"Kinkade","year":"2009","journal-title":"Genes Dev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.juro.2009.08.115","article-title":"Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer","volume":"183","author":"Shariat","year":"2010","journal-title":"J. Urol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1158\/0008-5472.CAN-17-2528","article-title":"A DDX31\/Mutant\u2013p53\/EGFR axis promotes multistep progression of muscle-invasive bladder cancer","volume":"78","author":"Daizumoto","year":"2018","journal-title":"Cancer Res."},{"key":"ref_51","first-page":"232","article-title":"Prognostic Value of p53 expression intensity in urothelial cancers","volume":"27","author":"Qamar","year":"2017","journal-title":"J. Coll. Physicians Surg. Pak."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/14728222.2017.1297798","article-title":"Tp53 and its potential therapeutic role as a target in bladder cancer","volume":"21","author":"Ciccarese","year":"2017","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12957-016-0890-9","article-title":"p53 status correlates with the risk of progression in stage T1 bladder cancer: A meta-analysis","volume":"14","author":"Du","year":"2016","journal-title":"World J. Surg. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.juro.2009.05.024","article-title":"p53 predictive value for pT1-2 N0 disease at radical cystectomy","volume":"182","author":"Shariat","year":"2009","journal-title":"J. Urol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs\u2014Part A: Renal, penile, and testicular tumours","volume":"70","author":"Moch","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_56","first-page":"49.e23","article-title":"FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy11This work was supported by Grant CB-2011-04-01 from Korean Foundation for Cancer Research grant and by a Global Frontier Project Grant (NRF-M1AXA002-2010-0029795) of the National Research Foundation funded by the Ministry of Education, Science and Technology of Korea","volume":"32","author":"Sung","year":"2014","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"148","DOI":"10.30699\/ijp.14.2.148","article-title":"Role of FGFR3 in Urothelial Carcinoma","volume":"14","author":"Akanksha","year":"2019","journal-title":"Iran. J. Pathol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/hmg\/dds486","article-title":"Oncogenic FGFR3 gene fusions in bladder cancer","volume":"22","author":"Williams","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"ref_59","first-page":"1","article-title":"A decade of FGF receptor research in bladder cancer: Past, present, and future challenges","volume":"2012","author":"Tomlinson","year":"2012","journal-title":"Adv. Urol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.juro.2016.12.096","article-title":"FGFR3, TERT and OTX1 as a urinary biomarker combination for surveillance of patients with bladder cancer in a large prospective multicenter study","volume":"197","author":"Beukers","year":"2017","journal-title":"J. Urol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrclinonc.2017.195","article-title":"Multiomic profiling refines the molecular view","volume":"15","author":"Hurst","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.eururo.2008.06.013","article-title":"FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours","volume":"55","author":"Zwarthoff","year":"2009","journal-title":"Eur. Urol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.juro.2011.09.008","article-title":"The FGFR3 mutation is related to favorable pT1 bladder cancer","volume":"187","author":"Liu","year":"2012","journal-title":"J. Urol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2005.05.1771","article-title":"Prospective study of fgfr3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas","volume":"24","author":"Hernandez","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"67435","DOI":"10.18632\/oncotarget.11883","article-title":"Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up","volume":"7","author":"Critelli","year":"2016","journal-title":"Oncotarget"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/MOU.0b013e328356ad0e","article-title":"Biomarkers for bladder cancer aggressiveness","volume":"22","author":"Frantzi","year":"2012","journal-title":"Curr. Opin. Urol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/path.2207","article-title":"FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer","volume":"213","author":"Tomlinson","year":"2007","journal-title":"J. Pathol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.eururo.2016.12.016","article-title":"Liquid biopsy analysis of FGFR3 and PIK3CA hotspot mutations for disease surveillance in bladder cancer","volume":"71","author":"Christensen","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1002\/ijc.29526","article-title":"Mutations inTERTpromoter andFGFR3and telomere length in bladder cancer","volume":"137","author":"Hosen","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/path.2507","article-title":"The development of multiple bladder tumour recurrences in relation to the FGFR3mutation status of the primary tumour","volume":"218","author":"Kompier","year":"2009","journal-title":"J. Pathol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Kompier, L.C., Lurkin, I., van der Aa, M.N.M., van Rhijn, B.W.G., van der Kwast, T.H., and Zwarthoff, E.C. (2010). FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0013821"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/path.5143","article-title":"FGFR3 mutation increases bladder tumourigenesis by suppressing acute inflammation","volume":"246","author":"Foth","year":"2018","journal-title":"J. Pathol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00000421-199606000-00013","article-title":"TPA, TATI, CEA, AFP, \u03b2-HCG, PSA, SCC, and CA 19-9 for monitoring transitional cell carcinoma of the bladder","volume":"19","author":"Pectasides","year":"1996","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/0169-5002(93)90246-T","article-title":"Serum tumor markers CEA, CA 50, TATI, and NSE in lung cancer screening","volume":"10","author":"Hakama","year":"1993","journal-title":"Lung Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/00365510152567068","article-title":"Serum tumour markers CA 15-3, TPA, TPS, hCG \u03b2 and TATI in the monitoring of chemotherapy response in metastatic breast cancer","volume":"61","author":"Alfthan","year":"2001","journal-title":"Scand. J. Clin. Lab. Investig."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/clinchem\/35.5.869","article-title":"Concentrations of tumor-associated trypsin inhibitor and C-reactive protein in serum in acute pelvic inflammatory disease","volume":"35","author":"Paavonen","year":"1989","journal-title":"Clin. Chem."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.3109\/00365528608996455","article-title":"Elevated pancreatic secretory trypsin inhibitor levels during severe inflammatory disease, renal insufficiency, and after various surgical procedures","volume":"21","author":"Lasson","year":"1986","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/ijc.2910310606","article-title":"Excretion of a tumor-associated trypsin inhibitor (TATI) in urine of patients with gynecological malignancy","volume":"31","author":"Huhtala","year":"1983","journal-title":"Int. J. Cancer"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1159\/000276919","article-title":"Evaluation of TATI and CYFRA 21-1 in patients with head and neck squamous cell carcinoma","volume":"59","author":"Goumas","year":"1997","journal-title":"ORL"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3109\/08860229809045114","article-title":"Serum levels of tumor associated trypsin inhibitor (TATT) and glomerular filtration rate","volume":"20","author":"Tramonti","year":"1998","journal-title":"Ren. Fail."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3109\/00365519109104618","article-title":"Biology and function of tumor-associated trypsin inhibitor, tati","volume":"51","author":"Stenman","year":"1991","journal-title":"Scand. J. Clin. Lab. Investig."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1093\/clinchem\/48.8.1206","article-title":"Tumor-associated trypsin inhibitor","volume":"48","author":"Stenman","year":"2002","journal-title":"Clin. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0090-4295(03)00329-7","article-title":"Tumor-associated trypsin inhibitor as a prognostic factor during follow-up of bladder cancer","volume":"62","author":"Kelloniemi","year":"2003","journal-title":"Urology"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.eururo.2005.04.034","article-title":"Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder","volume":"48","author":"Shariat","year":"2005","journal-title":"Eur. Urol."},{"key":"ref_86","first-page":"95","article-title":"Differential expression of trypsinogen and tumor-associated trypsin inhibitor (TATI) in bladder cancer","volume":"28","author":"Hotakainen","year":"2006","journal-title":"Int. J. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00345-011-0727-7","article-title":"Association of tumor-associated trypsin inhibitor (TATI) expression with molecular markers, pathologic features and clinical outcomes of urothelial carcinoma of the urinary bladder","volume":"30","author":"Patschan","year":"2011","journal-title":"World J. Urol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/9\/3360\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:27:17Z","timestamp":1760174837000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/9\/3360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,9]]},"references-count":87,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,5]]}},"alternative-id":["ijms21093360"],"URL":"https:\/\/doi.org\/10.3390\/ijms21093360","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,9]]}}}